At last, a mechanism by which KRas mutated tumors elaborate tumor resistance to KRas inhibitors was shown to involve ERK1/2-mediated phosphorylation of IRE1, thus preventing its degradation by the ERAD machinery (120). Here, KRAS is linked to neoplasm.